Alkermes ALKS Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Aristada And Aristada Initio | $390.39M+14.6% | $370.04M+6.9% | $369.44M+11.0% | $356.04M+7.9% | $340.79M+4.4% | |
| LYBALVI | $369.03M+25.9% | $346.69M+23.8% | $329.53M+27.1% | $305.98M+30.1% | $293.05M+38.9% | |
| Vivitrol | $479.35M+4.1% | $467.91M+2.3% | $477.91M+12.3% | $470.44M+14.4% | $460.65M+14.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Alkermes break its business down?
- Alkermes (ALKS) reports revenue by product across 4 parts — Aristada And Aristada Initio, LUMRYZ, LYBALVI and Vivitrol. Each is extracted from the segment footnotes and tracked over time.
- Where does Alkermes's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Alkermes's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
